Minoryx Therapeutics, membre de CataloniaBio & HealthTech, ha presentat la sol·licitud d'autorització de comercialització (MAA) del seu fàrmac leriglitazona a l'Agència Europea de Medicaments (EMA) per al tractament d’homes adults amb adrenoleucodistròfia lligada al cromosoma X (X-ALD). L'EMA ja ha validat el dossier de la sol·licitud i ara es troba en procés de revisió del Comitè de Medicaments d'Ús Humà (CHMP).

Specipig, member of CataloniaBio &HealthTech, has opened a neonatal intensive care unit (NICU) at its research facilities in the Barcelona area to continue responding to the global demand for preclinical Contract Research Organization (CRO) services.

Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences, a biotechcompany exclusively focused on advancing new therapies for children withcancer, announced they have entered a partnership to collaborate in thediscovery and development of innovative therapies for pediatric sarcomas.

Aniling, a biotech company that develops solutions based on next-generation genomic and epigenomic sequencing (NGS) methods for precision oncology, has obtained CE certification for its first in vitro diagnostic (IVD) tests for chronic lymphocytic leukaemia, colorectal cancer and liquid. The biotech is a  CataloniaBio & HealthTech member and one of the finishers of the IVD Accelerator  Programme, promoted by the association to help accelerate start-ups and companies in the field of in vitro diagnostics. The CE mark authorises the company to market the tests throughout Europe.

Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparing the clinical efficacy of implementing the proprietary MAFTEST® for selection of patients for adjuvant bisphosphonates therapy with current clinical guidance. Inbiomotion is participated by Ysios Capital, both CataloniaBio & HealthTech members.

CataloniaBio & HealthTech brought together nearly 400 executives, entrepreneurs, investors  and stakeholders in the biomedical and health sector in Catalonia at a new  edition of the summer barbecue on 14 July at the Specipig facilities. The association and the sector are growing, and the attendance figures reflect this. This year the BBQ has had the support as silver sponsors of Asabys, Caixa Capital Risc, Capital Cell, GENESIS Biomed, Inveready, Invivo  Ventures and Ysios Capital.

WIVI Vision, a CataloniaBio & HealthTech  member, signed an agreement with Federópticos to start a first phase of  implementation of their technology. The Federópticos’ opticians could offer new solutions in visual health to their patients.

Agomab Therapeutics ha anunciat recentment l’extensió de la seva Series B amb 40,5 milions de dòlars addicionals, uns 38,4 milions d’euros, arribant al tamany de ronda de 114 milions de dòlars.

Butler Scientifics, through its AutoDiscovery software, is collaborating on the study of immune profiles in COVID-19 patients and their impact on severity and treatment, recently published in the Journal of Clinical  Medicine.

Abzu is named a Cool Vendor in the 2022 Gartner® Cool Vendors in AI Governance and Responsible AI — From Principles to Practice report, an annual evaluation of commercial platforms for data science and machine learning (ML), as well as for cloud AI services platforms. These platforms use common open-source libraries for explainability, fairness, and trustworthiness, in addition to their own proprietary approaches.

WIVI Vision's solution, which assesses the capabilities of the visual system and designs and applies personalised treatments to possible dysfunctions, is advancing in its expansion thanks to the agreement signed with the CECOP group. This alliance will allow the start-up company, a member of CataloniaBio & HealthTech, to have access to the group's extensive network of associates, which has more than 800 stores distributed throughout Spain.

Gebro Pharma Laboratories, a CataloniaBio  & HealthTech member, recently signed an agreement with Novartis Farmacéutica, S.A. with Novartis Farmacéutica, S.A. under which, as of June 2022, it will be responsible for the national distribution of the Swiss company's drugs Xiliarx® and Icandra®. Both drugs belong to the category of oral antidiabetics for the treatment of type 2 diabetes in adults.

ENDRA and CDTI Innvierte lead the new investment bringing up to €7million the total funds raised by Amelia Virtual Care in the last year, together with current  investors Sabadell Asabys, Caixa Capital Risc and CG Ventures. In 2019  Amelia closed a €6 million Series A led by Sabadell Asabys, a CataloniaBio & HealthTech member, and Caixa Capital Risc which allowed them to further develop its technology and consolidate its presence in Europe and the US.

The European Commission has announced the 74 innovative companies selected for the first round of the EIC  Accelerator 2022. Among the selected companies there is Newborn Solutions, member of CataloniaBio &  HealthTech, with the project "The first Medical Device for non-invasive detection and monitoring of infant meningitis", a non-invasive  technology for screening and monitoring of serous fluid infections.

A clinical trial shows that rinsing the mouth for one minute with mouthwashes containing 0.07% Cetylpyridinium Chloride (CPC) reduces the number of infectious viruses in saliva such as SARS-CoV-2. A study led by the Fight Infections Foundation together with the IrsiCaixa AIDS Research Institute with the collaboration of DENTAID Research Center, a CataloniaBio  & HealthTech member.

Just a few months after the close of the Shared Value programme, all the companies that completed it are now at various stages along the path to implementing sustainability in their business models and activity. A total of 10 companies completed the programme and the B Impact Assessment (BIA) self-assessment process. The programme is the first initiative launched by the CataloniaBio  & HealthTech Sustainability  Workgroup with the aim of improving companies’ competitiveness by equipping them with tools to consider their impact on society.

Wen Wen will be responsible for the legal matters relating to the management company, funds, and portfolio companies. Her knowledge and experience will be key in all stages of the investment process from the negotiation of letters of intent and shareholders’ agreements to all legal aspects of the divestment process. In her role as Head of Legal, she will also ensure the accomplishment of the anti-money laundering regulations and will manage the communication with regulatory entities.

Last May GENESIS Biomed received the award to the best biomedical consultancy of the XI Edition of the National Awards El Suplemento in an event that took place at the Palace Hotel in Madrid, and which also coincided with the month of the fifth anniversary of the constitution of GENESIS Biomed, thus representing an unexpected gift.

CataloniaBio & HealthTech has received this year 2022 the positive resolution to the application to enter the register of Agrupaciones  Empresariales Innovadoras (AEI), from the Directorate General of Industry and SMEs (Ministry of Industry, Trade and Tourism).

Berlin-based company Cara Care has announced the closing of a $7 million financing round led by international food and nutrition producer Dr. Schär AG, which also involved existing investors Sabadell Asabys and Johnson & Johnson Innovation - JJDC, Inc, who led the Series A financing round. The investment lays the foundation for the international growth of Cara Care’s digital gastrointestinal therapeutics.